Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Human Mutation

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/humu.22496PMID 24352906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations

  2013cited by this paper
• The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer

  2013influential reference
• Aspirin use and risk of colorectal cancer according to BRAF mutation status.

  2013cited by this paper
• KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines

  2013cited by this paper
• Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

  2013influential reference
• Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

  2012cited by this paper
• Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma

  2012cited by this paper
• Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012influential reference
• Intratumor heterogeneity: evolution through space and time.

  2012cited by this paper
• Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

  2012cited by this paper
• Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

  2011cited by this paper
• Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

  2011cited by this paper
• KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

  2011cited by this paper
• Pyrosequencing cut‐off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules

  2011cited by this paper
• KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

  2011cited by this paper
• Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy

  2011cited by this paper
• Stem cells and their implications for colorectal cancer

  2011cited by this paper
• A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

  2010cited by this paper
• Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas.

  2010cited by this paper
• Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.

  2010cited by this paper
• Molecular circuits of solid tumors: prognostic and predictive tools for bedside use

  2010cited by this paper
• Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.

  2010cited by this paper
• KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results.

  2010cited by this paper
• The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

  2010cited by this paper
• The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.

  2010cited by this paper
• Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.

  2010cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.

  2010cited by this paper
• Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

  2010cited by this paper
• PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

  2009cited by this paper
• Targeting PI3K signalling in cancer: opportunities, challenges and limitations

  2009cited by this paper
• Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

  2009influential reference
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

  2009influential reference
• EGFR and colon cancer: a clinical view

  2008cited by this paper
• PIK3CA cancer mutations display gender and tissue specificity patterns

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers

  2008cited by this paper
• Prognostic and predictive factors in colorectal cancer

  2008cited by this paper
• Many different tumor types have polyclonal tumor origin: evidence and implications.

  2008cited by this paper
• PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

  2007cited by this paper
• Absence of tyrosine kinase mutations in Japanese colorectal cancer patients

  2007cited by this paper
• Novel mutant‐enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer

  2007cited by this paper
• Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population

  2007influential reference
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma

  2007cited by this paper
• The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

  2006cited by this paper
• Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

  2006cited by this paper
• Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.

  2006influential reference
• Recurrent KRAS codon 146 mutations in human colorectal cancer

  2006cited by this paper
• Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin.

  2006cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• Mutation analysis of p53, K‐ras, and BRAF genes in colorectal cancer progression

  2005cited by this paper
• Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

  2005cited by this paper
• The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck

  2005cited by this paper
• The prevalence of PIK3CA mutations in gastric and colon cancer.

  2005influential reference
• Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.

  2005cited by this paper
• Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

  2005influential reference
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004influential reference
• Oncogenic Mutations of PIK3CA in Human Cancers

  2004cited by this paper
• Oncogenic mutations of PIK3CA in human cancers.

  2004cited by this paper
• Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.

  2003cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• ras oncogenes in human cancer: a review.

  1989cited by this paper

• Search for Mutations Connected With Non‐Response to Anti‐EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours

  2025cites this paper
• Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors

  2025cites this paper
• The RAS/BRAF genes status in patients with colorectal cancer (review)

  2024cites this paper
• Molecular mechanisms of colorectal cancer formation and their significance (literature review)

  2024cites this paper
• Fast Genotyping of K-Ras Codons 12 and 13 Based on Streptavidin Magnetic Microbeads Equipped with Biotin-Coupled Single Base-Pair Mismatch Pcr (Sm-Pcr)

  2023cites this paper
• KRAS and BRAF Mutation Rates and Survival Outcomes in Colorectal Cancer in an Ethnically Diverse Patient Cohort

  2023cites this paper
• Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

  2022cites this paper
• Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review

  2022cites this paper
• Actionable Mutation Profile of Sun-Protected Melanomas in South America

  2022cites this paper
• Mechanisms of lymphatic spread in colon cancer: insights from molecular and genetic studies

  2022cites this paper
• Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.

  2022cites this paper
• Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted Resistance in Colorectal Cancer: From the Perspective of Cancer Community Ecology

  2021cites this paper
• Multi‐ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy

  2021cites this paper
• High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer

  2020cites this paper
• The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer

  2020cites this paper
• Tumorheterogenität am Beispiel des Kolonkarzinoms

  2020influential citation
• Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements

  2020cites this paper
• Genomic profiling of sporadic liver metastatic colorectal cancer.

  2020cites this paper
• Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review

  2019cites this paper
• University of Groningen RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

  2019cites this paper
• RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies.

  2019cites this paper
• RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

  2019cites this paper
• Melatonin as a potential inhibitor of colorectal cancer: Molecular mechanisms

  2019cites this paper
• Factors affecting KRAS mutation detection in colorectal cancer tissue.

  2019cites this paper
• Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate

  2018cites this paper
• Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer

  2018cites this paper
• The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy.

  2018influential citation
• Spatio-temporal tumor heterogeneity in metastatic CRC tumors: a mutational-based approach

  2018cites this paper
• Biology of Nodal Spread in Colon Cancer: Insights from Molecular and Genetic Studies

  2018cites this paper
• Analysis of KRAS Gene Mutations by using of Circulating Tumor DNA

  2018cites this paper
• Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients

  2017cites this paper
• Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival.

  2017cites this paper
• Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer

  2017cites this paper
• Innovative Disease Model: Zebrafish as an In Vivo Platform for Intestinal Disorder and Tumors

  2017cites this paper
• Gene Expression Profiling of Colorectal Cancer by Correlation with 18 F-FDG Kinetics as Measured by Dynamic Positron Emission Tomography-Computed Tomography ( dPET-CT ) : Dependency on Cadherin-Related Genes and Hypoxia

  2017cites this paper
• Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations

  2017cites this paper
• Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.

  2017cites this paper
• Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.

  2017cites this paper
• بررسی جهشهای رایج ژنهای KRAS و BRAF در بیماران مبتلا به کارسینومای بافت سنگفرشی سر و گردن

  2017cites this paper
• Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer

  2017cites this paper
• Closed-Tube PCR with Nested Serial Invasion Probe Visualization Using Gold Nanoparticles.

  2017cites this paper
• Common mutations assay of KRAS and BRAF genes in patients affected with Head and neck squamous cell carcinoma (HNSCC)

  2017cites this paper
• Advancing Techniques and Insights in Circulating Tumor Cell (CTC) Research

  2017cites this paper
• Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer

  2017cites this paper
• KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.

  2017cites this paper
• Colorectal cancer carcinogenesis: a review of mechanisms

  2016cites this paper
• RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.

  2016cites this paper
• Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

  2016cites this paper
• Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer

  2016cites this paper
• High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer

  2016cites this paper
• Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers

  2016cites this paper
• Tumor Heterogeneity and Single‐cell Analysis of CTCs

  2016cites this paper
• Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy

  2016cites this paper
• Single‐cell profiling approaches to probing tumor heterogeneity

  2016cites this paper
• Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer

  2016cites this paper
• Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.

  2016cites this paper
• Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cites this paper
• Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.

  2015cites this paper
• Badanie molekularnych markerów wykorzystywanych w leczeniu chorych na raka jelita grubego

  2015influential citation
• Non‐invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients

  2015cites this paper
• Novel molecular insights from routine genotyping of colorectal carcinomas.

  2015cites this paper
• Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

  2015cites this paper
• Challenges and opportunities for next-generation sequencing in companion diagnostics

  2015cites this paper
• Characterization of endoscopic ultrasound fine-needle aspiration cytology by targeted next-generation sequencing and theranostic potential.

  2015cites this paper
• Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica

  2015cites this paper
• Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

  2014influential citation
• Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories

  2014cites this paper
• Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation.

  2014cites this paper
• Understanding Cancer Mutations by Genome Editing

  2014cites this paper
• Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

  2014cites this paper
• BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications

  2014cites this paper
• Ras in digestive oncology: from molecular biology to clinical implications

  2014cites this paper
• Next-generation sequencing in precision oncology: challenges and opportunities

  2014cites this paper